Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $109.2 million.

  • Barinthus Biotherapeutics' Liabilities and Shareholders Equity fell 4212.65% to $109.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $541.1 million, marking a year-over-year decrease of 3145.84%. This contributed to the annual value of $160.3 million for FY2024, which is 2525.76% down from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Liabilities and Shareholders Equity stood at $109.2 million for Q3 2025, which was down 4212.65% from $129.6 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Liabilities and Shareholders Equity registered a high of $286.1 million during Q1 2022, and its lowest value of $109.2 million during Q3 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' median Liabilities and Shareholders Equity value was $230.0 million (recorded in 2023), while the average stood at $218.4 million.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Liabilities and Shareholders Equity skyrocketed by 45405.01% in 2021, and later crashed by 4212.65% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $280.7 million in 2021, then fell by 3.74% to $270.2 million in 2022, then dropped by 20.61% to $214.5 million in 2023, then dropped by 25.26% to $160.3 million in 2024, then tumbled by 31.89% to $109.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $109.2 million in Q3 2025, compared to $129.6 million in Q2 2025 and $142.0 million in Q1 2025.